Objective: This was a cross-sectional study of the ability of independently living healthy elders to follow a medication regimen. Participants were divided into a group with High Cognitive Function (HCF) or Low Cognitive Function (LCF) based on their scores on the ADAS-Cog. Method: Thirtyeight participants aged 65 or older and living independently in the community followed a twice-daily vitamin C regimen for 5 weeks. Adherence was measured using an electronic 7-day pillbox. Results: The LCF group had significantly poorer total adherence than the HCF group (LCF: 63.9 ± 11.2%, HCF: 86.8 ± 4.3%, t 36 = 2.57, p = .007), and there was a 4.1 relative risk of non-adherence in the LCF group as compared to the HCF group. Discussion: This study has important implications for the conduct of clinical drug trials, as it provides strong evidence that even very mild cognitive impairment in healthy elderly has a detrimental impact on medication adherence.
Method Participants
Participants aged 65 or older with a Mini-Mental State Examination (MMSE; Folstein, Folstein, & McHugh, 1975) score greater than 23 were recruited from two continuing care retirement communities in Oregon. All participants were living independently and were currently managing their own medication regimen on a daily basis. All participants believed that they were taking their current medications correctly as prescribed, and agreed to add a twice-daily vitamin regimen to their schedule. All participants provided written informed consent.
Clinical Assessments
Age, living status (alone or with another person), and years of schooling were collected for each participant. Cognitive function was assessed using a number of tests. There have been a wide range of tests developed to assess early cognitive loss, both clinically and for research purposes (Collie & Maruff, 2002) . As our goal was to identify individuals with very mild impairments, we chose tests that have shown construct validity for differentiating memory and cognitive loss in such individuals (Ihl, Frolich, Dierks, Martin, & Maurer, 1992) . The Alzheimer's Disease Assessment Scale-Cognitive Subtest (ADAS-Cog; Graham, Cully, Snow, Massman, & Doody, 2004 ) was used as a more comprehensive measure of cognitive function than is afforded by the MMSE because it is widely used to assess cognitive function in clinical trials for dementia drugs. In addition to administering the ADAS-Cog, we also collected delayed Word List Recall scores (Welsh, Breitner, & Magruder-Habib, 1993) , which are also sensitive to mild memory loss (Weaver Cargin, Maruff, Collie, & Masters, 2006) . We used parts A and B of the Trail Making Test (Drane, Yuspeh, Huthwaite, & Klingler, 2002) which is used clinically to assess attention deficits (O'Donnell, Macgregor, Dabrowski, Oestreicher, & Romero, 1994) . A Clinical Dementia Rating scale (Morris, 1993) score was assigned to each participant; this scale is often used clinically to identify patients with mild cognitive impairment. Finally, we also used the Instrumental Activities of Daily Living scale of the Older Americans Resources and Services (OARS) questionnaire (Fillenbaum & Smyer, 1981) to assess functional abilities of the participants. This test includes a measure of the assistance needed to manage medications, which was of direct relevance to our study.
To classify participants into those with very mildly degraded cognitive function versus those that were relatively higher in function, we first identified the age-adjusted norm for the ADAS-Cog scores and the 95% confidence intervals around those norms (Graham et al., 2004) . Scores greater than the value specified by the upper limit on the 95% confidence interval were considered to be significantly poorer than the age-adjusted norm (higher scores on the ADAS-Cog represented poorer performance). We then classified participants whose ADAS-Cog scores were above this limit as a low cognitive function (LCF) group comprising 18 participants (7 men, 11 women). The remainder of the participants was designated as a higher cognitive function (HCF) group comprising 20 participants (5 men, 15 women). It is important to note that although the participants in the HCF group had lower (better) ADAS-Cog scores, both groups of participants were clinically healthy, community-dwelling elders who managed their own medications on a daily basis. By commonly used criteria for amnesic mild cognitive impairment (MCI; Petersen, 2004) , 3 of the 18 participants in the LCF group had word-list recall scores worse than 1.5 SD outside of the norms for their age, although 6 had a single test of the battery that was >1.5 SD. None of the participants complained of memory impairment. Thus, the LCF group represented a group of elders whose cognitive function was somewhat compromised as compared to healthy age-matched norms, but they were functioning independently in their community.
Procedures
We conducted a mock 5-week drug trial to estimate adherence in each group of participants. During this trial, participants took a 250mg vitamin C supplement twice daily at predetermined times. Participants were asked to identify two times at which they would take their vitamin supplement, as close to 12 hr apart as possible (e.g., 7 a.m. and 7 p.m.). Medication adherence was measured using a 7-day reminder pillbox called the MedTracker (Figure 1 ) which we developed previously (Hayes, Hunt, Adami, & Kaye, 2006) . Participants loaded the pillbox with the vitamin supplements once a week. The 1st week of data were discarded; this initial period was intended to reduce error introduced by learning to use the MedTracker pillbox itself. Participants were also asked to complete a self-assessment questionnaire about their adherence during the monitoring period.
Adherence to the vitamin regimen was measured in two ways, consistent with reporting of adherence in drug trials (Paes et al., 1997) . Figure 2 shows how adherence was calculated. First, total adherence was estimated as the percentage of days in the trial period in which fewer than the prescribed two doses were taken. Regimen adherence was estimated as the percentage of doses that were not taken within 1 hr before, or 2 hr after, the prescribed time. An individual was considered to have poor adherence for a particular measure if their adherence by that measure was less than 80% (Ho, Magid, Masoudi, McClure, & Rumsfeld, 2006; Osterberg & Blaschke, 2005) .
In addition to adherence numbers, we also looked at how closely the participants adhered to the time regimen and the nature of missed doses. Because the instrumented pillbox reports the time at which each compartment is opened, we were able to track how late (or early) pills were taken, as well as when
Figure 1 The Instrumented Pillbox Used in This Study
Note: The 7-day reminder box was identical to that used by many participants to manage their nonstudy medications.
572 Journal of Aging and Health incorrect compartment was opened and when multiple compartments were opened. Determining what openings were errors required a heuristic approach, as there was no way of recording the participant's intention. For example, if the person accidentally took a pill from the wrong compartment one day and then the next day recognized the mistake and "caught up" by taking the previous day's pill, this would appear as two errors rather than just the first error. Nonetheless, the patterns of errors have the potential to provide additional insight into issues of adherence. The heuristic used to interpret the error data were as follows:
Figure 2 Plot of Data From One Participant
Note: The abscissa is the date of monitoring (shaded bars show alternating days) and the ordinate shows the time of day the pill was taken. The dots indicate the times at which pills were taken. The solid horizontal lines indicate the morning and evening time at which pills were supposed to be taken; the dotted horizontal lines delineate 1 hr before this time and 2 hr after this time-that is, the window during which the participant was considered to be adherent to the regimen. The arrows show pills that were taken outside of this window. The X's indicate that a pill was missed. Total adherence is then calculated as the percentage of days in which two pills were taken (for this participant, 71.4%). Adherence to regimen is calculated as the percentage of days in which pills were taken within the specified window (78.6%). Regimen adherence can also be calculated for morning only (91.4%) or evening only (65.7%).
1. If all 7 compartments were opened within 10 min, the participant was assumed to be loading the device. 2. Otherwise, if a pill compartment was opened on the wrong day, this was considered an error. However, if this was the only compartment opened at the required time for the current dose, then the pill was considered to have been taken and was counted toward good adherence as well as being counted as an error. This situation could arise, for example, if the participant remembered to take their pill but forgot what day it was. 3. If multiple pill containers were opened during the same dose interval, then the incorrect days were all considered to be errors unless the participant was loading the device.
Analysis
Adherence data were analyzed using a Student's t test for planned comparisons between groups. Relative risks of adherence were also calculated. Because the number of nonstudy medications taken differed between groups, the data were also analyzed using a 2-way ANOVA with group and number of medications as independent variables and total adherence as the dependent variable. For the latter analysis, the number of medications was represented as an ordinal variable (6 or fewer medications, and more than 6 medications).
Results

Participants
Thirty-eight participants (12 men, 26 women; mean age = 82.8 ± 5.5 years; mean education = 16.4 ± 2.1 years) were recruited for the study. Demographic and clinical test scores for the two groups are shown in Table  1 . There were no differences between groups in age or education level, or in their MMSE, instrumental activity of daily living, or clinical dementia rating scores. None of the participants reported that they required assistance in managing their medications. By design, the LCF group had a higher mean ADAS-Cog score (poorer performance) than the HCF group (HCF: 6.0 ± 2.1, LCF: 9.9 ± 2.1, t 36 = -5.81, p < .001). The LCF group also had a more missed words on the delayed Word List Recall (HCF: 3.4 ± 1.4, LCF: 5.6 ± 2.7, t 36 = -3.14, p < .002). Delayed Word List Recall has been shown to be highly sensitive to early memory loss in older adults with no clinical impairments (Weaver Cargin et al., 2006) , and therefore a poorer score on the delayed Word List Recall was not unexpected for this group. There were no significant differences between groups in their scores on the Trails A (HCF: 91.1 ± 1172.9, LCF: 109.1 ± 3084.7, t 27 = -1.191, p = .12) or Trails B (HCF: 141.2 ± 2120.0, LCF: 159.6 ± 6205.1, t 27 = -0.865, p = .20).
The LCF group took a somewhat greater number of nonstudy medications (HCF: 5.7 ± 2.5, LCF: 6.9 ± 3.5, t 36 = -1.26 p = .11), although they did not differ in the frequency with which they took those medications (HCF: 2.5 ± 0.8, LCF: 2.3 ± 1.0 times per day). Figure 3 shows the difference in adherence between the groups. Comparisons of both total adherence (taking the vitamins twice daily) and regimen adherence (meeting the predetermined dosage schedule) showed that the LCF group were significantly less adherent than the healthy elders. On average, the HCF group had excellent total adherence, unlike the LCF group (HCF: 86.8 ± 4.3%, LCF: 63.9 ± 11.2%, t 36 = 2.57, p = .007). There was also a significant difference in the regimen adherence, although the HCF group had somewhat lower adherence by this measure than by the total adherence measure (HCF: 76.9 ± 6.2%, LCF: 62.1 ± 7.0%, t 36 = 1.78, p = .04). To determine if these differences in adherence were due primarily to poor adherence by the 3 participants in the LCF group who met the criteria for amnesic MCI, we repeated the analysis excluding those individuals. Excluding these participants, the LCF group were still significantly less adherent than the HCF group on total adherence (HCF: 86.8 ± 4.3%, LCF: 63.4 ± 11.3%, t 33 = 2.54, p = .008 for total adherence; HCF: 76.9 ± 6.2%, LCF: 64.0 ± 6.6%, t 33 = 1.50, p = .07 for regimen adherence).
Adherence
Since the LCF group took somewhat more medications on average than the HCF group (t = -1.26, p < .11), we also did an ANCOVA to control for this difference. Even controlling for the number of medications taken by each group, the total adherence of LCF group was still significantly worse than that of the HCF, F(1, 35) = 7.95, p = .008. Note: The four measures include adherence to a twice-daily schedule, adherence to the prescribed regimen (dose taken 1 hr before or 2 hr after the prescribed times), adherence to the morning regimen, and adherence to the afternoon regimen. All measures were significantly different between groups (see text).
Participants with at least 80% adherence were considered to have good adherence. Only 27.8% of the LCF group had good adherence to their regimen by this measures, as compared to 75% of the HCF (relative risk of poor adherence = 4.1, CI = [3.47, 4.78], χ 2 = 8.43, p < .003). In both groups, participants had more trouble taking their medications in the evening than in the morning, with 65.8% achieving good adherence to the morning regimen but only 39.5% achieving good adherence to the afternoon regimen. The pattern was the same for both groups.
Qualitative Assessments
Self-report of medication-taking revealed that participants were not aware of how often they missed taking their vitamins. In all, 93% of participants reported that they had "excellent adherence" (i.e., they took their vitamins on time at least 80% of the time), although only 53% of participants actual were adherent to regimen (across both groups). Furthermore, 12% of participants believed that they had never missed a dose, when in fact only 5.3% of participants had 100% adherence by this measure.
When participants were asked to indicate reasons why they missed a pill, 62.2% reported that they were too busy to take it, and 59.5% reported that they were not home when they were supposed to take it. None of the participants reported that they missed a pill because they did not want to take it, they did not feel well enough to take it, or they were not sure when they were supposed to take it. Interestingly, 3 participants (1 HCF, 2 LCF) reported that they took the pill out of the box but forgot to take it, suggesting that even with detailed tracking of pill-taking, adherence may be overestimated in some cases.
Discussion
We have shown in this study that older people living independently and minding their own medication regimens have a wide range of medication adherence-some do well and others adhere poorly to the regimen. Importantly, the characteristic that distinguished the ability to adhere to the regimen was relatively impaired cognitive function. None of these individuals was demented. The degree to which cognition was impaired or degraded in these participants would not be apparent to a casual observer. Even in the LCF group, only 3 could qualify for mild cognitive impairment, and the results were not different with these individuals removed from the analysis.
The participants themselves were also not fully aware of their inability to adhere to the regimen.
The pattern of cognitive deficit associated with being in the LCF did not map to a consistent cognitive domain across the study group. The LCF group scored significantly worse on the total ADAS-Cog (a global cognitive measure) by design. Among the subtests of the ADAS-Cog, the memory domain scores were significantly worse in the LCF group compared to the HCF group. However, the greatest difference between the groups was in the nonmemory subtests. In theory, deficits in memory or planning and executive function would be assumed to have the most impact on medication taking. There was no difference in Trails test performance suggesting that, at least to the degree that this test measures planning and executive function, there was not a difference based on this domain. Insel and colleagues recently reported that a composite of executive function and working memory was a significant predictor of reduced medication adherence in a population (Insel, Morrow, Brewer, & Figueredo, 2006) . Although they did not report the raw scores of their participants, making it difficult to draw conclusions about the clinical level of functioning of their participants, their study supports the hypothesis that the complex task of medication taking requires the efficient functioning of multiple cognitive processes in concert. This, coupled with our current study, would suggest that medication regimen adherence may be a very sensitive marker of early functional decline.
Our study had some limitations. We asked people to take a vitamin C tablet twice a day which is not a standard regimen. Participants also took only the study vitamins using the pillbox and therefore had to follow the study protocol in addition to their daily medication regime. Participants may have not felt that it was important to take this nonessential supplement. However, the task itself was the same for all participants, and at least 63% had good adherence to their regimen. We only followed their adherence behavior for 5 weeks. Although there may have been increased adherence seen after a longer time period of follow-up, there was no evidence in trends in the data to suggest this, and the literature suggests that regimen adherence typically decreases over time in the absence of focused intervention (Osterberg & Blaschke, 2005; Weycker, Macarios, Edelsberg, & Oster, 2006) . Of course, we must be cautious in generalizing these results to all older persons, and further study of different populations with different medication regimens in particular would be instructive.
This study has important implications for healthy aging. Populationbased, longitudinal studies of medication adherence outcomes have shown significantly greater all-cause hospitalization and mortality for nonadherent patients, including those with diabetes mellitus and ischemic heart disease (Ho, Magid, et al., 2006; and for survivors of acute myocardial infarction (Rasmussen, Chong, & Alter, 2007) . In a study of 2169 community-dwelling older people, Yee and colleagues found that drug-related visits accounted for 12.6% of all emergency room visits, at a cost of $1.5 million over a 12-week period (Yee, Hasson, & Schreiber, 2005) . Of these visits, 19% were directly related to medication nonadherence. Clearly, proper medication adherence is essential to maintaining health. The results of the current study suggest that within community-dwelling elders, adherence may relate more closely to cognitive status than has previously been shown. It is also possible that subtle cognitive impairments due to common chronic medical illnesses such as diabetes, chronic obstructive pulmonary disease, or heart failure may critically impair medication taking effectiveness.
Finally, these results have important implications for clinical drug trials among older people. Rarely, except in studies of treatment of cognitive decline itself, is cognitive function assessed in any detail. Because the results of this study suggest that very mild cognitive deficits may have a profound impact on medication taking, it is important that adherence during the trial be monitored closely if cognitive function is even mildly compromised. Furthermore, the degree to which medication adherence in a clinical trial is assessed over time, especially when the underlying condition itself (or the drug being studied) can affect cognition, needs to be reconsidered. Thus a drug's efficacy may be incorrectly judged because of a lack of presumed biological effect, when in fact the problem was an effect on cognition leading to poor adherence to the drug.
